Severe Chronic Obstructive Pulmonary Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for severe chronic obstructive pulmonary disease. 105 active patents protecting 2 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
105
Active US patents
65/100
Avg vulnerability
$2.8B
Annual revenue covered

Originators in Severe Chronic Obstructive Pulmonary Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Arcutis 68 patents AstraZeneca K.K. 37 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating severe chronic obstructive pulmonary disease. Each bar = one year. Y-axis scaled to peak year (65 patents).

6
26
2
28
3
29
8
30
6
31
4
36
65
37
2
38
2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Daliresp
ROFLUMILAST
 Arcutis 68 62 — 2037-06-07
Pulmicort Respules
BUDESONIDE
 AstraZeneca K.K. 37 68 $2.8B 2026-11-09

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9119863 Pulmicort Respules method of use 93 2026-11-09
8975243 Pulmicort Respules method of use 93 2026-11-09
8497258 Pulmicort Respules method of use 93 2026-11-09
11357859 Pulmicort Respules method of use 88 2028-11-12
8491932 Pulmicort Respules method of use 83 2029-05-07
8324192 Pulmicort Respules method of use 81 2029-08-03
10716753 Pulmicort Respules method of use 76 2030-05-28
9415009 Pulmicort Respules method of use 76 2030-05-28
12005051 Daliresp method of use 75 2037-06-07
12310956 Daliresp method of use 75 2037-06-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9132093 Pulmicort Respules formulation 48 2031-09-07
10307375 Pulmicort Respules formulation 48 2031-09-07
10660858 Pulmicort Respules formulation 48 2031-09-07
11833292 Pulmicort Respules formulation 50 2038-10-05
11331442 Pulmicort Respules formulation 50 2038-10-05
11793796 Daliresp formulation 50 2037-06-07
9884050 Daliresp formulation 50 2037-06-07
10940142 Daliresp formulation 50 2037-06-07
9884050 Daliresp formulation 50 2037-06-07
10940142 Daliresp formulation 50 2037-06-07

Related